TX-MARY-KAY-ASH-FOUNDTN
In celebration of its 25th anniversary and guided by Mary Kay Ash’s dream to enrich the lives of women worldwide, the Mary Kay Ash FoundationSM released its first-ever Foundation Annual Report, as well as a new name, logo website and rebranding. Since 1996, the Foundation has contributed more than $80 million to organizations aligned with its two-fold mission: funding research for cancers affecting women and ending domestic violence and gender-based violence against women and girls.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005237/en/
For more than two decades, the Foundation has continued to innovate as a global charitable leader focused on women. To commemorate its milestone anniversary, the organization made a slight name change from The Mary Kay FoundationSM to Mary Kay Ash FoundationSM to improve search engine optimization. In addition, the Foundation unveiled a new logo and website, rebranding and the first-ever Mary Kay Ash FoundationSM Annual Report . The report gives an overview of the 2020 initiatives in the United States and around the world. Key findings in the report include:
- In 2020, the Mary Kay Ash FoundationSM awarded grants totaling $1,825,000 to causes in the U.S. and those that will make a difference throughout the world via the Innovative/Translational Cancer Research Grants and the International Post-Doctoral Fellowship Cancer Research Program . Since 1996, the Mary Kay Ash FoundationSM has supported innovative cancer research and clinical trials to find a cure for cancers affecting women by awarding more than $25 million for over 250 cutting-edge projects at leading medical schools and research institutions worldwide.
- Due to the COVID-19 pandemic, a devastating increase was reported in domestic violence across the world in 2020. This pandemic within a pandemic stretched domestic violence shelters to their limits. The Mary Kay Ash FoundationSM awarded emergency grants totaling $1,000,000 to support domestic violence frontline workers – the first responders for women and children. In an effort to expand a global commitment to eradicate gender-based domestic violence, Mary Kay Inc. and the Mary Kay Ash FoundationSM joined forces with the United Nations Trust Fund to End Violence Against Women and CARE USA , humanitarian global leaders. Since 2000, the Foundation has donated more than $58 million to ending gender-based violence. The effort has supported over six million women and girls seeking shelter and services from abuse.
“Twenty-five years ago, my grandmother, Mary Kay Ash, created the Foundation that continues to remain at the heart of Mary Kay Inc., company employees and independent beauty consultants who strive to uphold her vision of making the world a better place for women and their families,” said Ryan Rogers, Chief Investment Officer and Vice President of the Mary Kay Ash FoundationSM Board of Directors. “While the Mary Kay Ash FoundationSM planted its roots in Texas and watched them spread across the United States, much like the company itself, the work of the Foundation knows no borders. We envision a world where women are empowered, healthy and safe. On this milestone anniversary, we continue our steadfast commitment to women worldwide and are reminded of how truly honored we are to continue doing my grandmother’s work.”
For more information, visit marykayashfoundation.org .
About the Mary Kay Ash FoundationSM
Guided by Mary Kay Ash’s dream to enrich the lives of women everywhere, the Mary Kay Ash FoundationSM raises and distributes funds to invest in breakthrough cancer research to find a cure for women-related cancers and ending domestic violence against women. Since 1996, the Mary Kay Ash FoundationSM has contributed more than $80 million to organizations aligned with its two-fold mission. In addition, the Foundation supports awareness initiatives, community outreach programs, and advocates for legislation to ensure women are healthy and safe. Together, we can make the world better for women. To learn more about how to educate, advocate, volunteer and donate, and join life-saving work to support and empower women, visit marykayashfoundation.org , find us on Facebook and Instagram , or follow us on Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005237/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
